Oragenics Inc (OGEN)
1.05
-0.01
(-0.94%)
USD |
NYAM |
Apr 26, 16:00
1.05
0.00 (0.00%)
After-Hours: 20:00
Oragenics SG&A Expense (Quarterly): 1.754M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.754M |
September 30, 2023 | 1.333M |
June 30, 2023 | 1.116M |
March 31, 2023 | 1.249M |
December 31, 2022 | 0.8872M |
September 30, 2022 | 1.216M |
June 30, 2022 | 1.044M |
March 31, 2022 | 1.332M |
December 31, 2021 | 1.078M |
September 30, 2021 | 0.8471M |
June 30, 2021 | 1.370M |
March 31, 2021 | 1.977M |
December 31, 2020 | 1.196M |
September 30, 2020 | 1.01M |
June 30, 2020 | 0.8083M |
March 31, 2020 | 1.519M |
December 31, 2019 | 0.8983M |
September 30, 2019 | 0.8528M |
June 30, 2019 | 1.026M |
March 31, 2019 | 0.9804M |
December 31, 2018 | 1.031M |
September 30, 2018 | 1.184M |
June 30, 2018 | 1.012M |
March 31, 2018 | 0.7955M |
December 31, 2017 | 0.5971M |
Date | Value |
---|---|
September 30, 2017 | 0.925M |
June 30, 2017 | 0.7913M |
March 31, 2017 | 0.8652M |
December 31, 2016 | 0.932M |
September 30, 2016 | 1.102M |
June 30, 2016 | 0.9406M |
March 31, 2016 | 0.8498M |
December 31, 2015 | 0.8549M |
September 30, 2015 | 0.7619M |
June 30, 2015 | 0.7323M |
March 31, 2015 | 0.8155M |
December 31, 2014 | 0.8119M |
September 30, 2014 | 0.5651M |
June 30, 2014 | 1.177M |
March 31, 2014 | 0.7674M |
December 31, 2013 | 2.359M |
September 30, 2013 | 2.558M |
June 30, 2013 | 1.519M |
March 31, 2013 | 1.103M |
December 31, 2012 | 1.285M |
September 30, 2012 | 1.597M |
June 30, 2012 | 0.8355M |
March 31, 2012 | 1.308M |
December 31, 2011 | 1.214M |
September 30, 2011 | 1.364M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.8083M
Minimum
Jun 2020
1.977M
Maximum
Mar 2021
1.185M
Average
1.116M
Median
Jun 2023
SG&A Expense (Quarterly) Benchmarks
Palatin Technologies Inc | 3.033M |
Inogen Inc | 50.43M |
Cyclacel Pharmaceuticals Inc | 1.873M |
Actinium Pharmaceuticals Inc | 2.306M |
MAIA Biotechnology Inc | 2.660M |